Ageing Res Rev 112: 102834
Led by Troy Watson , our clinic combines Semaglutide GLP-1 with tailored lifestyle guidance to support sustainable weight loss
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
We live in a world where sadly, the way that we look can influence how others look at us, judge us, and sometimes affect the opportunities that we do or dont get because of our physical appearance
Heres a breakdown of every major injectable peptide used for fat loss and how it stacks up